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Abstract
Aims: Type 2 diabetes is characterised by increased plasma concentrations of pro-inflammatory
cytokines [such as tumour necrosis factor – alpha; TNF-α] and soluble forms of adhesion molecules
involved in leukocyte – endothelial interactions. These molecules are synthesised as
transmembrane proteins and the plasma soluble forms are generated by ectodomain cleavage from
the cell surface by members of the ADAM [adisintegrin and metalloproteinase] proteinase family.
We hypothesised that plasma low density lipoprotein [LDL] from subjects with Type 2 diabetes
would influence in vitro monocytic ADAM and matrix metalloproteinase [MMP] gene expression
differently compared to control LDL.
Methods: We examined relative mRNA expression by real time PCR in a monocytic cell line
[THP-1] cultured for 4, 8 and 24 hrs with human plasma LDL derived from subjects with [n = 5]
or without [n = 4] Type 2 diabetes. Gene expression for MMP-1 and 9, and ADAM – 8, 15, 17 and
28 was studied.
Results: Type 2 diabetes LDL significantly increased gene expression of MMP – 1 [p < 0.01] MMP
– 9 [p < 0.001], and ADAM 17 [p < 0.05], – 28 [p < 0.01] and – 15 [p < 0.01] compared to control
LDL. Type 2 diabetes LDL had disparate effects on inhibitors of MMP.
Conclusion: These data suggest that Type 2 diabetes LDL could lead to increased adhesion
molecule and TNF alpha cell surface shedding, and vascular plaque instability, by promoting
increased expression of ADAM and MMP genes.
Background
Type 2 diabetes is characterised by elevated circulating lev-
els of pro – inflammatory cytokines such as Tumour
Necrosis Factor alpha [TNF-α] and the soluble forms of
adhesion molecules involved in leukocyte – endothelial
cell interactions, such as intercellular adhesion molecule-
1 [ICAM-1], vascular cell adhesion molecule-1 [VCAM-1]
and E-selectin. [1]. These abnormalities may be athero-
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genic, and overexpression and release of TNF-α may have
a role in the development of insulin resistance and Type 2
diabetes [2].
Cell surface adhesion molecules and TNF-α are synthe-
sised as transmembrane proteins, and the plasma soluble
forms are generated by ectodomain cleavage from the cell
surface. Ectodomain shedding of cell membrane forms is
mediated by certain members of the ADAM [a disintegrin
and metalloproteinase] proteinase family [3]. The cata-
lytic domain of ADAMs share homology with the matrix
metalloproteinases [MMP], which have a role in vascular
plaque stability [4]. ADAM17 is involved in shedding vas-
cular cell adhesion molecule 1 [VCAM-1] [3], L-selectin
[3] and other cell membrane proteins including TNF-α
and its receptor [3]. The ADAM proteinases also have a
role in cell: cell and/or cell: matrix interactions [3]. The
elevated plasma levels of soluble TNF-α and some adhe-
sion molecules in Type 2 diabetes could imply increased
activity or expression of ADAMs in these observations.
Plasma LDL from people with Type 2 diabetes is structur-
ally and biochemically different, and commonly mini-
mally oxidatively modified [5]. However, it is unknown
how modified LDL derived from people with Type 2 dia-
betes influences MMP or ADAM gene expression in vitro or
in vivo. We have previously shown in monocytic cells that
ADAM mRNA expression can be regulated by PPAR-
gamma agonists [6], which is relevant as components of
oxidatively modified LDL can be agonists of PPAR-
gamma. We hypothesised that plasma LDL from people
withType 2 diabetes would influence in vitro monocytic
ADAM and MMP gene expression differently compared to
control LDL.
Methods
Subjects [Table 1]
After Ethical Committee approval and written informed
consent, we obtained fasting plasma LDL from subjects
with Type 2 diabetes [n = 5] or controls without diabetes
[n = 4]. All donors were Caucasian, non-smokers between
45 and 70 years old. Type 2 diabetes was defined as diag-
nosis after the age of 40 years, no history of ketosis and
with stable glycaemic control on diet or oral hypoglycae-
mics. Patients were excluded if they had hypertension,
clinically expressed coronary artery disease, were receiving
hormone replacement therapy, aspirin, HMG CoA reduct-
ase ['statin'] or insulin therapy. Patients with macropro-
teinuria were excluded. All controls had fasting plasma
glucose below 6.1 mmol/l.
LDL isolation and characterisation
LDL were isolated from fasted human plasma, containing
1 mg/ml EDTA [Na2] and 0.6% [w/v] sucrose, stored at -
70°C, using a short-run-ultracentrifugation method
based on non-equilibrium density gradient ultracentrifu-
gation. Oxidized LDL in each LDL was determined using
the Mercodia Oxidized LDL ELISA kit which measures the
aldehyde modification of apolipoprotein B lysine resi-
dues
Cell culture
THP-1 cells were maintained in RPMI 1640 [Life Technol-
ogies, UK] supplemented with 5 mM L-glutamine 100 U/
ml penicillin and streptomycin and 10% foetal calf serum,
at 37°C and 5% CO2. For experiments, cells were cultured
in serum free RPMI alone, or containing 25, 50 or 100
microg/ml Type 2 diabetes LDL and control LDL in tripli-
cate, for 4, 8 or 24 hours as indicated.
RNA isolation and Real Time PCR analysis
Total RNA was isolated using the RNA-Bee™ [Biogenesis]
according to the manufacturer's instructions. RNA [1
microg] was reverse transcribed in a 20 microl reaction
using SuperScript™ II reverse transcriptase [Invitrogen]
according to the manufacturer's instructions. Relative
mRNA expression [compared to 18S RNA] of ADAM8, 15,
17 and 28, MMP-1, -9 and 14 and TIMP-1, -3 and 4 were
measured by Taqman real time PCR [Perkin Elmer] as
described previously [6].
Experimental plan
The choice of genes for MMP, ADAM and metalloprotein-
ase inhibitors was based on our previous studies. [6].
Statistical analysis
Expression of mRNA for the gene of interest in each RNA
sample was calculated as a ratio with 18S RNA. Each bio-
logical triplicate was compared to mRNA expression by
untreated cells at the appropriate time point. All data was
assumed to be non normally distributed. Type 2 diabetes
[n = 5] and control [n = 4] values, all in triplicate, at each
concentration and time point were compared using
Mann-Whitney Rank Sum Test. LDL treatments at each
time point were compared to untreated controls using
Kruskal-Wallis test, with Dunn's Multiple comparison
test.
Results
Table 2 shows MMP, ADAM and TIMP mRNA expression
of cells treated with Type 2 diabetes LDL or control LDL
compared to the mRNA expression in untreated cells at
each time point.
Monocytic ADAM gene expression [Table 2]
ADAM gene expression in Type 2 diabetes LDL treated
cells was significantly higher compared to control LDL
treated cells for a] ADAM 28 after 4 and 24 hours at higher
LDL concentrations b] ADAM17 after 4 hours at higherCardiovascular Diabetology 2007, 6:21 http://www.cardiab.com/content/6/1/21
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Table 1: Baseline data for Type 2 diabetes and control plasma LDL donors
TYPE 2 DIABETES CONTROLS p
Number 54
Age [yrs] 63.6 [0.93] 53.0 [3.08] 0.02
Known Diabetes duration [yrs] 7.8 [0.66] -
M:F 02:03 02:02
Body Mass Index [kg/m2] 30.2 [1.66] 25.5 [0.5] ns
Waist – hip ratio 0.88 [0.02] 0.78 [0.05] ns
Diabetes treatment -
Diet 1
Sulphonylurea 2
Metformin 1
Sulphonylurea/metformin 1
HbA1c [%] 6.82 [0.56] 5.10 [0.10] ns
Total cholesterol [mmol/l] 6.68 [0.55] 6.33 [0.70] ns
LDL cholesterol [mmol/l] 4.30 [0.59] 4.4 [0.67] ns
Triglycerides [mmol/l] 2.56 [0.31] 1.39 [0.08] 0.036
HDL cholesterol [mmol/l] 1.22 [0.08] 1.32 [0.05] ns
Data shown as mean and [standard error of mean] ns = not significant.
Table 2: mRNA expression for ADAM and MMP genes in response to increasing human LDL concentrations (25,50 and 100 µg/ml from 
control or Type 2 diabetes donors) after 4,8 and 24 hours culture
LDL concentration (µg/ml)
25 50 100
CT 2 D MCT 2 D MCT 2 D M
MMP – 1
4 hrs 0.48 (0.09) 0.97 (0.21) 0.41 (0.14) 0.66 (0.11) * 0.29 (0.06) 0.62 (0.09) **
8 hrs 0.69 (0.08) 0.63 (0.07) 0.59 (0.05) 0.53 (0.08) 0.53 (0.07) 0.56 (0.05)
2 4  h r s ------
MMP – 9
4 hrs 0.98 (0.09) 1.36 (0.10) * 1.02 (0.15) 1.55 (0.13) * 1.01 (0.19) 1.98 (0.2) **
8 hrs 0.84 (0.05) 0.89 (0.07) 0.76 (0.05) 0.94 (0.05) * 0.73 (0.10) 0.94 (0.07) **
24 hrs 0.89 (0.06) 1.09 (0.06) 0.63 (0.04) 1.0 (0.07) *** 0.67 (0.09) 1.03 (0.08) **
TIMP – 1
4 hrs 0.73 (0.04) 0.88 (0.05) 0.74 (0.04) 0.86 (0.04) 0.73 (0.07) 0.90 (0.05) *
8 hrs 0.94 (0.06) 0.87 (0.04) 0.90 (0.05) 0.86 (0.03) 0.81 (0.04) 0.81 (0.04)
24 hrs 1.09 (0.06) 1.14 (0.07) 0.94 (0.06) 1.08 (0.05) 1.1 (0.10) 1.16 (0.06)
TIMP – 3
4 hrs 0.87 (0.04) 0.84 (0.04) 0.85 (0.03) 0.73 (0.04) ** 0.79 (0.02) 0.70 (0.04)
8 hrs 0.95 (0.04) 0.90 (0.06) 0.85 (0.04) 0.84 (0.04) 0.75 (0.04) 0.68 (0.040
24 hrs 0.99 (0.06) 0.87 (0.04) 1.01 (0.07) 0.84 (0.04) ** 0.96 (0.05) 0.86 (0.03)
ADAM – 28
4 hrs 0.76 (0.05) 1.07 (0.05) 0.83 (0.11) 1.07 (0.09) 0.78 (0.1) 1.23 (0.06) **
8 hrs 0.84 (0.06) 0.81 (0.04) 0.87 (0.07) 0.83 (0.05) 0.72 (0.05) 0.75 (0.06)
24 hrs 0.97 (0.07) 1.10 (0.07) 0.85 (0.05) 1.15 (0.09) * 0.95 0.11 1.06 (0.06)
ADAM – 17
4 hrs 0.93 (0.10) 1.19 (0.08) 0.81 (0.09) 1.13 (0.08) * 0.84 (0.12) 1.11 (0.06) *
8 hrs 0.94 (0.04) 1.03 (0.05) 0.93 (0.06) 0.86 (0.04) 0.79 (0.05) 0.78 (0.04)
24 hrs 1.08 (0.09) 1.15 (0.07) 0.92 (0.06) 1.13 (0.07) 1.14 (0.13) 1.17 (0.60)
ADAM – 15
4 hrs 0.91 (0.05) 1.07 (0.10) 0.96 (0.09) 1.18 (0.08) 0.91 (0.09) 1.21 (0.06) **
8 hrs 0.99 (0.4) 1.01 (0.06) 1.08 (0.07) 0.95 (0.04) 0.86 (0.04) 0.87 (0.05)
24 hrs 0.87 (0.03) 0.92 (0.07) 0.86 (0.05) 0.87 (0.05) 0.94 (0.08) 0.99 (0.06)
* p < 0.05 ** p < 0.01 *** p < 0.001 for Type 2 diabetes (T2DM) vs control (C) LDL treated cells mRNA expression at each matched LDL 
concentration and time. Data shown as a mean (SE)Cardiovascular Diabetology 2007, 6:21 http://www.cardiab.com/content/6/1/21
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LDL concentrations c] ADAM 15 at 4 hours at higher LDL
concentrations.
Monocytic MMP gene expression [Table 2]
MMP expression in Type 2 diabetes LDL treated cells was
significantly higher compared to control LDL treated cells
for a] MMP-1 after 4 and 8 hours at all LDL concentra-
tions, and b] MMP – 9 at 4, 8 and 24 hours at most LDL
concentrations.
Monocytic TIMP gene expression [Table 2]
TIMP-1 expression in Type 2 diabetes LDL treated cells
was significantly higher compared to control LDL treated
cells for at 4 hours at high LDL concentrations. TIMP-3
expression in Type 2 diabetesLDL treated cells was signif-
icantly lower compared to control LDL treated cells after 4
and 24 hours at higher LDL concentrations.
Oxidized LDL
No differences in electrophoretic mobility or oxidized
LDL content were detected between the control and Type
2 diabetes [Control LDL, 51.44 U/l ± SEM 6.67; Type 2
diabetes LDL, 39.98 U/l ± SEM 4.694. P = 0.225].
Discussion
We have shown that plasma LDL from subjects with Type
2 diabetes differs from control LDL in its effects on the
pattern of expression of MMP, ADAM and TIMP genes in
THP-1 monocytic cells. In vitro, Type 2 diabetes LDL pro-
moted the expression of the MMP-1, MMP-9, ADAM28,
ADAM17 and ADAM15 genes compared to control LDL.
This suggests the lipoprotein environment of circulating
and sub-endothelial monocytes in Type 2 diabetes could
promote altered shedding of membrane-bound cytokines,
receptors and adhesion molecules and alter cell-cell inter-
actions.
Ectodomain shedding by ADAM proteinases is highly rel-
evant in view of the well described but unexplained
increase in circulating soluble adhesion molecule concen-
trations and TNF-α in Type 2 diabetes [1]. The mechanism
[s] underlying this consistent observation are unknown
and it is not fully understood how ectodomain-shedding
is regulated in vivo. The present data is consistent with the
idea that Type 2 diabetes LDL could increase ADAM17
activity in THP-1 monocytes, and their ability to shed
TNF-α and VCAM-1 [7]. Type 2 diabetes LDL also induced
a significant increase in ADAM28 gene expression.
ADAM28 associates with integrin alpha 4 beta 1, the
receptor for endothelial VCAM-1 and CS-1 fibronectin,
and integrin alpha 4 beta 7, which binds VCAM-1, Mad-
CAM-1 and fibronectin. This suggests that ADAM28 could
be involved in regulating monocyte adhesion to the
endothelium.
Alterations in monocyte MMP expression induced by LDL
found in Type 2 diabetes LDL, [rather than artificially oxi-
dised LDL] has not been investigated before. These data
indicates a significant increase in MMP-1 and MMP-9
expression induced by Type 2 diabetes LDL compared to
control LDL. In atheromatous plaque, increased expres-
sion of MMP-1 and MMP-9 may decrease vascular plaque
stability and risk of plaque rupture [4]. If these observa-
tions are a reflection of in vivo interactions between LDL
and sub endothelial monocyte – macrophages, this could
promote increase vascular plaque instability in Type 2 dia-
betes.
Subtle differences in the compositions of control and
Type 2 diabetes LDL populations may be responsible for
the differences in gene expression in this paper as there
was no difference in the amount of apolipoprotein B oxi-
dised epitopes. A recent study comparing markers of LDL
oxidation found that LDL-ketocholesterol and plasma-ox-
apoB were significantly higher in Type 2 diabetes com-
pared to control LDL, but found no difference in levels of
lyso-phosphatidylcholine [5]. Others have shown both
palmitoyl and stearoyl-lyso-phosphatidylcholine to be
increased in Type 2 diabetes LDL [8].
One weakness of the present study is the age difference
between groups [Table 1]. We have found no relationship
between age variability between ages of 40 and 60 and
oxLDL concentrations in Type 2 diabetes or controls [9].
As far as we aware there are no data indicating significant
change in LDL components across the narrow age differ-
ence in this study. In addition, we should emphasise the
small group sizes in this study, the significant basline dif-
ferences in baseline plasma triglycerides, and the need to
repeat these observations in larger populations.
Despite these limitations, these data suggests that LDL
from subjects with Type 2 diabetes promotes increased
monocyte mRNA expression of MMP-1, MMP-9, and
ADAM proteinases responsible for inflammatory cytokine
and adhesion molecule shedding. These data suggest a
pathway between modification of LDL in Type 2 diabetes
increased MMP expression and ecto-domain cleavage of
adhesion molecules and TNF-α.
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